A Prescription for Success

Infographic | August 24, 2021

The life sciences sector has played a pivotal role amid the COVID-19 pandemic. To cope with the global crisis, traditional competitors partnered to accelerate research and develop the fastest novel vaccine in the history. Governments, health systems, payers, retail pharmacies, and nonprofits are now working collaboratively with the sector to provide widespread distribution and administration.

Infographic | May 20, 2022

This product titled One Page Pharmaceutical Industry World Economy Scenario Report Infographic PPT PDF Document is a completely editable document in A4 size designed in Powerpoint.

Infographic | January 13, 2020

Fewer than one in eight chronic-disease sufferers say they watch when a drug commercial comes on TV, according to one recent study of community users. And for the millennials among them, the percentage is even less so. That’s despite the $5.1 billion spent by biopharma on the medium in 2018. We take a look at these data points and many others from two recent studies on the media habits of patients and doctors.

Infographic | March 12, 2022

Pharmaceutical industry and medicine vector infographics with drugs, pills, bottles and packages, text blocks and charts all around

Infographic | February 25, 2020

Worldwide cancer drug sales are already way ahead of those of other drugs and the revenue generated by them is expected to grow even larger by 2024. This is according to a report recently released by consultancy Evaluate, which analyses trends in the pharmaceutical sector. According to Evaluate's calculations, oncology drugs reached US$123.8 billion in sales in 2018, more than double that of the next item on the list, drugs treating diabetes with US$48.5 billion dollars in sales. By 2024, cancer drug sales are expected to almost double to US$236.6 billion dollars.

Infographic | April 7, 2020

COVID-19 is a rapidly emerging and devastating pandemic disease. Recently, chloroquine (CQ) and hydroxychloroquine (HCQ) have been suggested for possible off-label use for patients suffering from a more severe clinical course.